A coordinated collaboration between clinicians, academic labs and industry CDMOs produced a bespoke CRISPR‑based therapy for an infant with a lethal urea cycle disorder in a matter of months. Children’s Hospital of Philadelphia led the clinical effort, with manufacturing and components supplied by Danaher‑affiliated groups, Aldevron, Integrated DNA Technologies and Acuitas for LNP delivery. The case report outlines regulatory, manufacturing and quality steps taken under urgent timelines, offering a template for rapid personalized gene‑editing interventions in single‑patient emergencies.